The more we know about our visitors, the easier it will be for us to publish everything you want to see.

Keep me logged in Forgot your password?

Please wait...

Please wait...

Methotrexate for injection

Compare Methotrexate for injection  to:
Compare
Compare

Generic Name for Methotrexate for injection

Methotrexate 1gram/vial; pwd for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free.

Legal Classification:

Rx

Pharmacological Class for Methotrexate for injection

Folic acid antagonist.

Manufacturer of Methotrexate for injection

Bedford Laboratories

Indications for Methotrexate for injection

Gestational choriocarcinoma. Chorioadenoma destruens. Hydatidiform mole.

Other Indications for Methotrexate for injection

Adult dose for Methotrexate for injection

See literature. Tablet form is often preferred when low doses are being administered. Choriocarcinoma and similar trophoblastic diseases: 15–30mg orally or by IM inj daily for 5 days; usually repeated 3–5 times as required with a rest period of ≥1 week between courses.

Children's dosing for Methotrexate for injection

Not applicable.

Also:

Contraindications for Methotrexate for injection

Pregnancy (Cat. X). Nursing mothers.

Warnings/Precautions for Methotrexate for injection

Be fully familiar with this drug's toxicity before use. Discontinue if malignant lymphomas occur. Obtain baseline and monitor CBCs with differential, platelet counts, chest X-ray, and hepatic, renal and pulmonary function. During therapy monitor hematology monthly, renal and hepatic function every 1–2 months, more often if increasing dose or predisposed to toxicity (eg, dehydration). Discontinue immediately if blood counts drop significantly. Rule out pregnancy in women of childbearing potential; use effective contraception during therapy and for at least 1 ovulatory cycle afterwards for women and for at least 3 months afterwards for men. Interrupt therapy if vomiting, diarrhea, stomatitis, or pulmonary symptoms occur. Hepatic or renal impairment. Obesity. Diabetes. Peptic ulcer. Ulcerative colitis. Infection. Dehydration. Folate deficiency. Ascites, pleural effusions: evacuate fluid, monitor for toxicity and reduce dose or discontinue if needed. Elderly (use low doses and monitor closely). Debilitated.

Interactions for Methotrexate for injection

Avoid live virus vaccines. Toxicity increased by NSAIDs, salicylates, phenytoin, sulfonylureas, sulfonamides, probenecid, folic acid antagonists. May be potentiated by penicillins (monitor), tetracyclines, chloramphenicol, non-absorbable broad spectrum antibiotics. May be antagonized by folic acid. May potentiate theophylline, mercaptopurine. Increased risk of soft tissue necrosis and osteonecrosis with radiotherapy. Caution with other hepatotoxic drugs (eg, azathioprine, retinoids, sulfasalazine) and nephrotoxic agents (eg, cisplatin).

Adverse Reactions for Methotrexate for injection

Ulcerative stomatitis, leukopenia, nausea, GI upset, malaise, fatigue, chills, fever, dizziness, infection, myelosuppression, hepatotoxicity, renal toxicity, CNS toxicity, seizures (esp in children); interstitial pneumonitis, tumor lysis syndrome, skin reactions (may be fatal; eg, toxic epidermal necrolysis, Stevens-Johnson syndrome).

How is Methotrexate for injection supplied?

Tabs—30
Soln (2mL, 4mL, 8mL, 10mL)—10 (single-use vials)
Pwd (1 gram)—1 (single-use vial)

Related Disease:

Cancer, breast
Cancer, head and neck
Cancer, lung
Chorioadenoma destruens
Choriocarcinoma, gestational
Hydatidiform mole
Mycosis fungoides
Non-Hodgkin's lymphoma

Related Resources

Adjuvant Radiochemotherapy Has Lasting Benefit in Gastric Cancer

May 18, 2012

Patients with gastric cancer who undergo resection show survival benefit 10 years later.

Fertility-Related Information Urgently Needed for Female Patients with Cancer

May 18, 2012

Young adult males and females with cancer receive vastly different amounts of fertility-related and fertility preservation information.

STAT3 Mutations ID'd in Rare Lymphoproliferative Disorder

May 18, 2012

Four specific mutations in SH2 domain seen in T-cell large granular lymphocytic leukemia.

Genetic Profiling Improves Prognosis of Uveal Melanoma

May 18, 2012

Gene expression profiling (GEP) and chromosomal analysis show prognostic value in patients with uveal melanoma.

Bisphosphonates Cut Skeletal Morbidity in Multiple Myeloma

May 18, 2012

Zoledronate superior to placebo or etidronate for improving overall survival.

AREDIA

Oncology > Leukemias, lymphomas, and other hematologic cancers

Pamidronate disodium 30mg; per vial; pwd for IV infusion after reconstitution; contains mannitol.

COSMEGEN

Oncology > Bladder, kidney, and other urologic cancers

Dactinomycin 500mcg/vial; lyophilized pwd for IV inj or regional perfusion after reconstitution; contains mannitol; preservative-free.

Fluorouracil

Oncology > Colorectal and other GI cancers

Fluorouracil 50mg/mL; soln for IV inj.

Fluorouracil

Oncology > Pancreatic, thyroid, and other endocrine cancers

Fluorouracil 50mg/mL; soln for IV inj.

TRISENOX

Oncology > Leukemias, lymphomas, and other hematologic cancers

Arsenic trioxide 1mg/mL; soln for IV inj after dilution; preservative-free.

Oncology > Cytoprotective and supportive care agents

Bisphosphonates (eg, Aredia, Zometa) may inhibit the activation of cancer-associated proteins through the suppression of geranyl-geranylation and farnesylation or inhibit ...
more »

'Teachable Moments' for Smoking Cessation in Patients Diagnosed with Cancer Underutilized

Debra Hughes February 16, 2012

Less than one-fifth (18.1%) of healthcare providers reported high levels of confidence in their ability to counsel patients with cancer who smoke to quit smoking, a survey published in The Oncologist online February 14 has found.

Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma

May 11, 2012

A look at the following clinical trial: Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma

Clinical Study of PM01183 in Patients With Acute Leukemia

May 10, 2012

A look at the following clinical trial: Clinical Study of PM01183 in Patients With Acute Leukemia

Diuretics for Hypertension

December 30, 2011

Hypertension dosing regiment chart for loop, potassium-sparing, and thiazide-like diuretics.

Calcium Channel Blockers Chart

December 30, 2011

Calcium channel blockers (CCB) used to treat hypertension (HTN) including benzothiazepines, dihydropyridines, and diphenylalkylamines.

Beta Blockers

December 30, 2011

Beta blocker pharmacokinetic comparison chart.

Angiotensin-Converting Enzyme (ACE) Inhibitors for Hypertension

December 30, 2011

Angiotensin-Converting Enzyme (ACE) Inhibitors and ACEI Combination Therapy Hypertension Dosing Chart.

Angiotensin II Receptor Blocker (ARB) for Hypertension

December 30, 2011

Angiotensin II Receptor Blockers (ARB) and ARB Hypertension dosing.


© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions